As Roche heads towards an FDA verdict on its CD20xCD3 bispecific Lunsumio for lymphoma before the end of this year, rivals from Regeneron and AbbVie are starting to nip at its heels, with new ...

Lymphomas are among the cancers most dependent ... These markers often start with the letters CD. For instance, B-cell markers (CD20 and CD79a), T-cell markers (CD3 and CD5), and other markers ...

The indication also covers DLBCL arising from low grade lymphoma and patients not eligible for autologous stem cell transplant. Monjuvi (tafasitamab) targets the CD-19, a protein on the surface of ...

With GCC2005, GC Cell is striving to fulfill a significant unmet need in oncology. T‑cell lymphomas, which often arise in extranodal lymphoid tissues, are highly aggressive and generally exhibit ...

Engineered to target the CD5 marker which is highly expressed on T-cell lymphomas GCC2005 co-expresses a chimeric antigen receptor (CAR) alongside interleukin-15 (IL-15). This dual expression ...